Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YHT-Enhanced MRI for Inflammatory Vascular Wall Pathology
ChiCTR2500108744Phase 2Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Sep 2025
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of glycosylated superparamagnetic iron oxide in atherosclerotic disease, arteritis, venous thromboembolism (VTE) and 3 more (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Loss of R2* signal (ΔR2* value), Vessel wall signal enhancement rate (SI%) and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
glycosylated superparamagnetic iron oxide
03
Conditions
atherosclerotic diseasearteritisvenous thromboembolism (VTE)intracardiac thrombosislymphatic diseases
Beyond the preview
Go deeper on ChiCTR2500108744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108744.